Project Grant R34AI184065
- This Project Grant award of $234,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate how Down syndrome affects the immune system. Specifically, the project will use a novel single-cell sequencing approach to analyze how the extra copy of chromosome 21 in Down syndrome disrupts the normal regulation of genes involved in the interferon immune response. The goal is to...
- The Department of Health and Human Services National Institutes of Health (NIH) awarded a $1,488,578 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Wisconsin-Madison to develop humanized mouse models for studying Down syndrome (DS) immune responses. The project aims to: 1) Create DS hypoimmune gene-edited induced pluripotent stem cell lines and differentiate them into cardiovascular cell therapies, assessing in vitro DS immune responses; and 2)...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
- This Project Grant award from the Department of Health and Human Services National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) provides $446,096 to the University of Illinois to develop and implement community-based participatory health research with young adults with Down syndrome. The project aims to reflect the perspectives and lived experiences of adults with Down syndrome, including those from underserved and underrepresented communities, to reduce health disparities and...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) will provide $1,257,163.00 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) for treating Alzheimer's disease and associated health conditions in individuals with Down syndrome. The project aims to first measure FSH levels across the lifespan in mouse models of...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $1,017,548 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of North Carolina at Chapel Hill. The grant, titled "HOME GROWN: A FAMILY-BASED LIFESTYLE INTERVENTION TO SUPPORT HEALTHY DEVELOPMENT OF YOUNG CHILDREN WITH DOWN SYNDROME," will fund a 2-phase study to evaluate the feasibility (R61 phase) and efficacy (R33 phase) of a tailored healthy...
- This Project Grant award of $456,390.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research on the regulation of the HA stem nanoparticle vaccine response by antigen duration in infants. The research aims to gain novel insights into how antigen duration and vaccine construct modulate the infant B and T cell immune response to influenza vaccines, with the goal of improving protective...
- This Project Grant award of $1,346,873 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is supporting research to establish an Alzheimer's disease biomarker clock in individuals with Down syndrome. The project aims to utilize positron emission tomography (PET) imaging and plasma analytes to longitudinally assess changes in amyloid, tau, and neurodegeneration biomarkers prior to the onset of dementia in this population. This research will address key...
- This Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is focused on investigating the susceptibility of basal forebrain cholinergic neurons in individuals with Down syndrome. The key objectives of this $111,783 award, which runs from November 9, 2024 to June 30, 2026, are to: 1) determine if there are fewer basal forebrain cholinergic neurons and earlier accumulation of Alzheimer's disease pathology in the early...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $195,041 supports research to elucidate the role of cardiovascular disease in the development of Alzheimer's disease in individuals with Down syndrome. The 2-year project will leverage data from the Alzheimer's Biomarker Consortium for Down Syndrome to develop innovative statistical models combining Bayesian inference and machine learning. These methods will explore...
This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $286,793 to the Benaroya Research Institute at Virginia Mason to prepare for a clinical trial testing the hypothesis that high-dose influenza vaccine safely improves vaccine response in people with Down syndrome under 65 years old. The key products and services to be delivered include: Finalizing the clinical trial design, completing start-up activities, and designing the mechanistic and epidemiological studies to evaluate if and how high-dose influenza vaccine is more effective than standard immunization for people with Down syndrome. Conducting a randomized-controlled clinical trial to compare the safety and efficacy of high-dose versus standard-dose influenza vaccine in 111 individuals with Down syndrome, with the primary endpoint of vaccine-specific antibody responses. The award period runs from September 24, 2025 to August 31, 2026 and aims to address an urgent public health need, as people with Down syndrome are at increased risk of death from respiratory infections and exhibit impaired response to influenza immunization.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $286.8k | 9/24/25 |